VANCOUVER, BC / ACCESSWIRE / February 13, 2017 / CVR Medical Corp. CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) previously announced its intention to complete a private placement financing for gross proceeds of up to $2,500,000 (the “Financing”), which is expected to consist of units, with each unit comprised of one common share and one-half of one common share purchase warrant at a proposed price of $0.33 per unit, or such other price per unit determined by CVR Medical management in compliance with TSX Venture Exchange (the “Exchange”) pricing regulations. After consultation with the Exchange, CVR Medical has amended the proposed purchase price of the Financing to $0.35 per unit. All other aspects of the Financing remain unchanged.
Completion of the Financing is subject to Exchange acceptance, and all securities issued pursuant to the Financing will be subject to a hold period of four months as required under applicable securities legislation.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888